Cough Hypersensitivity Syndrome Market

On 17 July 2026 GSK stopped developing camlipixant for refractory chronic cough after one of its two Phase III trials missed its goal, leaving gefapixant, approved in the European Union on 15 September 2023, as the only licensed drug aimed at the nerve pathway behind cough hypersensitivity syndrome. Douglas Insights values the cough hypersensitivity syndrome market at USD 2.10 billion in 2025 and forecasts USD 4.82 billion by 2035, a compound growth rate of 8.66%. The receipt is about 6.0 million treated patient-years worldwide in 2025 at an average USD 350 of treatment spend per patient-year. Treated patients grow 5.5% a year as specialist cough clinics and guidelines turn an overlooked symptom into a diagnosis, while spend per patient rises 3.0% a year as licensed P2X3 drugs and speech therapy take share from cheap generics. The report sits within Douglas Insights coverage of pharmaceuticals and follows the published Douglas Insights methodology.

What is cough hypersensitivity syndrome, and what does the market include?

Cough hypersensitivity syndrome is a chronic cough lasting more than 8 weeks in which the nerves of the airway overreact, so that small triggers such as talking, cold air or perfume set off bouts of coughing, and it underlies most refractory or unexplained chronic cough. Patients describe a constant tickle or urge to cough, and many cough hundreds of times a day. Treating asthma, reflux or nasal disease helps some patients, but the cough persists in others, and these refractory patients form the core of the cough hypersensitivity syndrome market. The market covers prescription spend on neuromodulators such as gabapentin, pregabalin and amitriptyline; low-dose opioids and other antitussives used for chronic cough; speech and behavioural cough suppression therapy; and P2X3 receptor antagonists such as gefapixant. It excludes over-the-counter cough and cold remedies, drugs for acute cough, and treatment of the underlying asthma, reflux or rhinitis. Value is spend at the price paid by health systems and patients.

What did GSK’s camlipixant decision change for the cough hypersensitivity syndrome market?

GSK’s decision removed the most advanced new drug from the cough hypersensitivity syndrome pipeline and cut the value Douglas Insights expects from licensed P2X3 drugs by about USD 400 million in 2035. GSK paid about USD 2.0 billion for Bellus Health in 2023 to gain camlipixant, a P2X3 blocker designed to cause less taste disturbance than gefapixant. On 17 July 2026 it reported that CALM-1 met its primary goal on 24-hour cough frequency at week 12 while CALM-2 missed statistical significance at week 24, and that the limited efficacy was unlikely to transform patient care. The decision follows the US Food and Drug Administration‘s second rejection of Merck’s gefapixant in December 2023, after an advisory committee voted 12 to 1 that the benefit had not been shown. Gefapixant, sold as Lyfnua, is approved in Japan since January 2022 and in the EU since September 2023 but not in the United States. P2X3 receptor antagonists therefore hold only 4% of 2025 value, USD 84 million, and cheap off-label medicines remain the backbone of cough hypersensitivity syndrome treatment.

How many people have cough hypersensitivity syndrome?

About 10% of adults worldwide report chronic cough, and Douglas Insights estimates that about 2% to 3% of adults have refractory or unexplained cough driven by cough hypersensitivity syndrome. Chronic cough is most common in women and people aged 50 to 70, and many patients cough for years before reaching a specialist. Of an estimated 100 million or more adults with refractory chronic cough worldwide, only about 6.0 million were treated for cough hypersensitivity syndrome in 2025, mostly in North America, Europe, Japan and China. Douglas Insights expects about 10.3 million treated patients by 2035 as diagnosis improves.

What drives cough hypersensitivity syndrome demand when fewer than 1 in 10 refractory patients reaches a specialist?

Better diagnosis is the first driver. The European Respiratory Society’s 2020 guidelines on chronic cough recognised cough hypersensitivity as a treatable condition and set out a pathway for refractory patients, and specialist cough clinics have spread across the UK, Europe, the United States, Japan and China. Douglas Insights estimates that the share of refractory chronic cough patients who receive a targeted treatment rises from about 6% in 2025 to about 9% by 2035, which on its own adds about 4 points a year to treated patient growth. Cough monitors that count coughs automatically over 24 hours also make the condition measurable in clinics and trials.

Guideline-backed neuromodulators are the second driver. Gabapentin and pregabalin, cheap generics first approved for epilepsy and nerve pain, reduced cough in randomised trials and are recommended for a trial in refractory patients. Neuromodulators hold 46% of 2025 cough hypersensitivity syndrome value, USD 966 million, and grow 7.68% a year to USD 2.02 billion by 2035 as more patients start treatment, although side effects such as drowsiness and dizziness limit how long many stay on them.

Non-drug therapy is the third driver. Speech and behavioural cough suppression therapy teaches patients to recognise the urge to cough and replace it with swallowing or breathing techniques, usually in 2 to 4 sessions, and works without the side effects of drugs. Speech and behavioural therapy holds 20% of 2025 value, USD 420 million, and grows 10.67% a year as health systems train more therapists and add remote sessions.

Licensed P2X3 drugs are the fourth driver. Gefapixant reduced 24-hour cough frequency by about 18.5% more than placebo at 12 weeks in COUGH-1 and 14.6% at 24 weeks in COUGH-2, and it is reimbursed in Japan and several European countries. Douglas Insights expects P2X3 receptor antagonists to grow from USD 84 million in 2025 to USD 595 million in 2035, the fastest segment at 21.63% a year, as prescribing widens in Japan and Europe and new P2X3 and other nerve-targeted drugs from Chinese and other developers reach Asian markets. Together the drivers lift average spend per treated patient from USD 350 in 2025 to about USD 470 in 2035.

What holds back cough hypersensitivity syndrome treatment when 40% of patients stop within 6 months?

Three restraints cut the 2035 cough hypersensitivity syndrome figure to about USD 3.27 billion in the slower case. Modest efficacy comes first: the best-studied drugs cut cough frequency by only 15% to 20% more than placebo, and the placebo response in cough trials is large, which makes regulators and payers cautious; the US rejection of gefapixant and GSK’s camlipixant decision show how hard it is to prove a clear benefit.

Side effects and safety come second: gefapixant causes taste disturbance in more than half of patients on the 45 mg dose, gabapentinoids cause drowsiness and carry misuse warnings, and even low-dose morphine faces tight prescribing rules in many countries, so Douglas Insights estimates about 40% of patients stop drug treatment within 6 months. Under-diagnosis comes third: many patients never see a specialist, primary care doctors often treat chronic cough with repeated courses of antibiotics, inhalers or reflux drugs, and fewer than 1 in 10 refractory patients reaches targeted cough hypersensitivity syndrome care today.

Which cough hypersensitivity syndrome treatment carries the value, the generic neuromodulator or the licensed P2X3 drug?

Neuromodulators lead with 46% of 2025 value. These cough hypersensitivity syndrome treatments earned USD 966 million, growing 7.68% a year, because gabapentin, pregabalin and amitriptyline are cheap, guideline-backed and prescribed by both specialists and family doctors. Opioids and other antitussives hold 30%, USD 630 million, and grow slowest at 5.18% a year, since prescribing rules limit low-dose morphine and codeine. Speech and behavioural therapy holds 20%, USD 420 million, growing 10.67% a year as a first choice for patients who want to avoid drugs. P2X3 receptor antagonists hold 4%, USD 84 million, and are the fastest-growing segment at 21.63% a year from a small base in Japan and Europe.

By care setting, Douglas Insights estimates specialist respiratory and ear, nose and throat clinics started about 55% of 2025 treated patients and primary care about 45%. By payer, public health systems and insurers paid about 80% of value and patients about 20%.

Where is cough hypersensitivity syndrome treated, from UK cough clinics to Japanese gefapixant prescriptions?

North America spends the most, 38% of 2025 value, and Asia Pacific is the fastest-growing region at 10.85% a year. North American cough hypersensitivity syndrome spend reached USD 798 million in 2025, growing 7.66% a year, driven by specialist cough clinics and higher drug and therapy prices, though no P2X3 drug is approved there. Asia Pacific holds 28%, USD 588 million, rising to USD 1.65 billion by 2035, led by Japan, the first country to approve gefapixant, and China, where chronic cough is common and hospital cough clinics are expanding. Europe holds 27%, USD 567 million, growing 7.36% a year, led by the UK, Germany and France, where the ERS guidelines and speech therapy services are best established. Latin America adds USD 84 million at 8.86% and the Middle East and Africa USD 63 million at 9.36%.

Which companies supply cough hypersensitivity syndrome treatments?

Cough hypersensitivity syndrome treatment is highly fragmented, because most spend goes on generic medicines and therapy services: Douglas Insights estimates the largest single supplier, Viatris, owner of the Neurontin and Lyrica brands, holds about 6% of 2025 value, and no company holds more than 10%. Merck, known as MSD outside North America, markets gefapixant as Lyfnua in Japan and Europe. Generic makers such as Teva, Sandoz and Sun Pharma supply most gabapentin, pregabalin, amitriptyline and low-dose morphine. Speech and language therapists in hospitals and private practice deliver behavioural therapy. GSK halted camlipixant in July 2026, and Trevi Therapeutics is testing oral nalbuphine extended-release in chronic cough, including cough in idiopathic pulmonary fibrosis. Suppliers win on guideline recommendations, reimbursement and tolerability. Inhaled respiratory drugs used for underlying causes are sized in our Aerosol Therapy Market report.

How much does a year of cough hypersensitivity syndrome treatment cost, from USD 100 generics to branded gefapixant?

Cough hypersensitivity syndrome treatment cost an average USD 350 per treated patient-year in 2025. Generic gabapentin or amitriptyline can cost less than USD 100 a year in many countries, while branded pregabalin and specialist-prescribed regimens cost more. A course of 2 to 4 speech and behavioural therapy sessions costs about USD 300 to USD 900 depending on the country. Gefapixant is priced as a branded specialty medicine and costs several times the generic options per year where it is reimbursed. The base case lifts average spend per treated patient to about USD 360 in 2026 and USD 470 by 2035 as licensed drugs and therapy take a larger share.

What is in the cough hypersensitivity syndrome pipeline?

The cough hypersensitivity syndrome pipeline is thinner after July 2026, with no late-stage P2X3 drug left in development in Western markets, Douglas Insights counts. Earlier candidates also stalled: Bayer discontinued eliapixant in 2022. Remaining approaches include nalbuphine extended-release, which acts on opioid receptors, and nerve-targeted drugs in early trials, including NK-1 receptor blockers and sodium channel blockers. Chinese developers are also testing P2X3 antagonists for local approval. Douglas Insights assumes no new drug class reaches wide use before 2030, so neuromodulators and therapy carry most growth through the forecast.

How could the cough hypersensitivity syndrome forecast change by 2035?

The cough hypersensitivity syndrome forecast ranges from USD 3.27 billion to USD 7.05 billion in 2035. The base case carries 5.5% growth in treated patients and 3.0% growth in spend per patient, for an 8.66% revenue CAGR and USD 4.82 billion. The slower scenario, with slow diagnosis, tighter controls on gabapentinoids and opioids and no new licensed drugs, sets the legs at 3.5% and 1.0%, for 4.54% growth. The faster scenario, with rapid spread of cough clinics and a new nerve-targeted drug approved in the United States by 2030, sets them at 7.5% and 5.0%, for 12.87% growth. Each 1-point change in treated-patient growth moves the 2035 figure by about USD 477 million. Over-the-counter pain and cold remedies, which sit outside this boundary, are sized in our Acetaminophen Market report.

Douglas Exclusive: the chronic cough treatment pathway tracker

The Douglas Exclusive tracker follows cough hypersensitivity syndrome patients through the care pathway in 12 countries, from chronic cough prevalence to specialist referral, diagnosis, first-line treatment and persistence, and records reimbursement status and price for each licensed drug and therapy. Licence holders receive it as a maintained tab in the Excel model, updated as trials read out and payers decide.

Which regulations and guidelines shape the cough hypersensitivity syndrome market?

Three layers of rules shape the cough hypersensitivity syndrome market, starting with the EU approval of gefapixant on 15 September 2023 and its US rejection in December 2023. Drug approval rules come first: regulators require a clear, clinically meaningful cut in cough frequency against a large placebo effect, which decides which drugs reach patients. Clinical guidelines come second: the ERS 2020 guidelines and the American College of Chest Physicians guidance on unexplained chronic cough recommend neuromodulators and speech therapy for refractory patients, shaping prescribing. Controlled-substance rules come third: gabapentin and pregabalin are controlled drugs in the UK since April 2019 and in several US states, and opioid prescribing limits restrict low-dose morphine, holding back the opioids and other antitussives segment.

What methodology sits behind the cough hypersensitivity syndrome model?

The cough hypersensitivity syndrome model is built bottom-up from about 6.0 million treated patient-years in 2025 at an average USD 350 each. It covers 4 treatment segments, 2 care settings and 5 regions. Patients come from chronic cough prevalence studies in 25 countries, multiplied by refractory share, specialist referral and treatment rates; spend comes from national drug price lists, reimbursement tariffs for therapy sessions and company disclosures. Over-the-counter cough remedies and treatment of underlying asthma, reflux and rhinitis are excluded, and growth is decomposed as treated patients times spend per patient. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.

Sources

1. GSK GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (2026)
2. European Medicines Agency Lyfnua (gefapixant) European public assessment report (2023)
3. European Respiratory Journal ERS guidelines on the diagnosis and treatment of chronic cough in adults and children (2020)